Vaginal Atrophy (GSM — Genitourinary Syndrome of Menopause)

Definition

GSM affects approximately 50% of postmenopausal women and involves a range of symptoms caused by estrogen-deficiency-induced changes in the vagina, vulva, and lower urinary tract: vaginal dryness, painful intercourse (dyspareunia), reduced lubrication, thinning of vaginal walls, urinary urgency, frequency, recurrent urinary tract infections, and increased susceptibility to vaginal infections. Unlike hot flashes and other vasomotor symptoms, which often improve over time, GSM tends to worsen without treatment. It is chronically under-discussed — many women do not report it because of embarrassment, and many clinicians do not ask. Local vaginal estrogen (cream, ring, tablet, or suppository) is highly effective, with very low systemic absorption and an excellent safety profile — even in most women with breast cancer history.

Frequently Asked Question

Is vaginal dryness and discomfort just something to accept after menopause?

Absolutely not. GSM is a treatable medical condition — not an unavoidable consequence of aging. Local vaginal estrogen is safe, effective, and produces no meaningful systemic absorption in most cases. It can reverse vaginal tissue changes, restore lubrication, reduce urinary urgency, and significantly improve sexual comfort and function. Women suffer through this unnecessarily because it goes undiscussed — not because treatment is unavailable.

Is vaginal estrogen safe if I have a history of breast cancer?

This is an individualized clinical decision made in consultation with the patient's oncologist. However, current data and guidelines from major oncology and menopause organizations suggest that low-dose local vaginal estrogen carries minimal systemic absorption and may be appropriate for many breast cancer survivors experiencing significant GSM symptoms. The clinical conversation is worth having rather than assuming all estrogen is contraindicated.

What is the difference between GSM and vaginal atrophy?

Vaginal atrophy was the older term used to describe the changes to vaginal tissue caused by estrogen deficiency. GSM — Genitourinary Syndrome of Menopause — is the updated clinical term adopted in 2014 to better reflect the full scope of the condition, which includes urinary as well as vaginal and vulvar symptoms. The preferred clinical term is now GSM, though many patients are more familiar with vaginal atrophy or vaginal dryness.

Why Vaginal Atrophy (GSM — Genitourinary Syndrome of Menopause) Matters

GSM profoundly affects quality of life, sexual health, intimate relationships, and urinary function — yet it is almost universally undertreated due to lack of clinical conversation. Defining it clearly on SPOKEmed's site signals that this is a safe, clinical topic to raise, reducing the barrier for patients who have been suffering in silence.

How Spokmed Company Uses It

SPOKEmed addresses GSM as a core component of postmenopausal care. Local vaginal estrogen therapy is a primary tool — low-dose, high-efficacy, and appropriate for most women including many who cannot use systemic HRT. Full evaluation includes assessment of symptoms, urinary health, and sexual function as part of comprehensive hormone care.

Related Services

Related Terms

"Vaginal Atrophy (GSM — Genitourinary Syndrome of Menopause)" Appears in These Categories

Hormone Health & Life Stage Transitions